AZRX AZURRX BIOPHARMA

AzurRx BioPharma CEO Issues Letter to Shareholders

AzurRx BioPharma CEO Issues Letter to Shareholders
EN
07/10/2020

Underlying

AZRXAZURRX BIOPHARMA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AZURRX BIOPHARMA

 PRESS RELEASE
Free
AZRX AZURRX BIOPHARM...

AzurRx BioPharma to Change Corporate Name to First Wave BioPharma Toda...

AzurRx BioPharma to Change Corporate Name to First Wave BioPharma Today Company to begin trading on Nasdaq under new ticker symbol, “FBWI”, effective September 22 BOCA RATON, Fla., Sept. 21, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX) (“First Wave” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced that it will begin operating under its new corporate name, First Wave BioPharma, Inc., effective today upon the completion of certain filings with th...

September 21, 2021 1 EN
 PRESS RELEASE
Free
AZRX AZURRX BIOPHARM...

AzurRx BioPharma CEO Issues Letter to Shareholders Regarding Recent Ac...

AzurRx BioPharma CEO Issues Letter to Shareholders Regarding Recent Acquisition of First Wave Bio and Creation of First Wave BioPharma BOCA RATON, Fla., Sept. 14, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today issued a letter to its shareholders from James Sapirstein, President, Chief Executive Officer and Chairman, regarding its recently announced merger with First Wave Bio, Inc....

September 14, 2021 1 EN
 PRESS RELEASE
Free
AZRX AZURRX BIOPHARM...

AzurRx BioPharma Announces Acquisition of First Wave Bio and its Propr...

AzurRx BioPharma Announces Acquisition of First Wave Bio and its Proprietary Niclosamide Formulations Targeting Multi-Billion Dollar Inflammatory Bowel Disease Indications AzurRx BioPharma to be renamed “First Wave BioPharma” and trade under new NASDAQ ticker symbol, “FWBI” Three IBD clinical indications, including ulcerative colitis and Crohn’s disease, added to GI therapeutic pipeline with multiple near-term inflection points Conference call scheduled for today at 8:30 a.m. ET BOCA RATON, Fla., Sept. 13, 2021 (GLOBE NEWSWIRE) --   (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company...

September 13, 2021 1 EN
 PRESS RELEASE
Free
AZRX AZURRX BIOPHARM...

AzurRx BioPharma Announces Reverse Stock Split

AzurRx BioPharma Announces Reverse Stock Split Common Stock Will Begin Trading on Split-Adjusted Basis on September 13, 2021 BOCA RATON, Fla., Sept. 10, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: ), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 10 pre-split shares. AzurRx’s common stock will continue ...

September 10, 2021 1 EN
 PRESS RELEASE
Free
AZRX AZURRX BIOPHARM...

AzurRx BioPharma Activates New Clinical Trial Sites in India for Phase...

AzurRx BioPharma Activates New Clinical Trial Sites in India for Phase 2 RESERVOIR Trial Evaluating Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections Phase 2 placebo-controlled clinical trial to confirm safety of FW-1022 and investigate its ability to remove SARS-CoV-2 virus from the GI tract BOCA RATON, Fla., Sept. 10, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic, therapies for gastrointestinal (GI) diseases, today announced the activation of seven (7) n...

September 10, 2021 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch